A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics.
Olanow, CW, RA Hauser, J Jankovic, W Langston, A Lang, W Poewe, E Tolosa, et al. 2008. “A Randomized, Double-Blind, Placebo-Controlled, Delayed Start Study to Assess Rasagiline As a Disease Modifying Therapy in Parkinson’s Disease (the ADAGIO Study): Rationale, Design, and Baseline Characteristics.”. Mov Disord.